Presented By
Harvoni, the first single medication to treat hepatitis C, was recently approved by the FDA.
Gilead Sciences

The Food and Drug Administration approved the first single medication to treat hepatitis C on Friday, green-lighting one pill in the place of multiple treatments. The new drug, Harvoni, is the third hepatitis C drug approved in the past year.

“With the development and approval of new treatments for hepatitis C virus, we are changing the treatment paradigm for Americans living with the disease,” said FDA official Edward Cox.

Harvoni, developed by Gilead Sciences, will be the first hepatitis drug to require a pill only once daily. A full 12-week treatment will cost $94,500, less than existing treatments, Reuters reports.

More Must-Reads From TIME

Write to Justin Worland at justin.worland@time.com.

You May Also Like
EDIT POST